14 results on '"DCOG-LATER Study Group"'
Search Results
2. Risk of benign meningioma after childhood cancer in the DCOG-LATER cohort: Contributions of radiation dose, exposed cranial volume, and age
- Author
-
Kok, J.L., Teepen, J.C., Leeuwen, F.E. van, Tissing, W.J.E., Neggers, S.J.C.M.M., Pal, H.J. van der, Loonen, J.J., Bresters, D., Versluys, B., Heuvel-Eibrink, M.M. van den, Dulmen-den Broeder, E. van, Heiden-van der Loo, M. van der, Aleman, B.M.P., Daniels, L.A., Haasbeek, C.J.A., Hoeben, B., Janssens, G.O., Maduro, J.H., Oldenburger, F., Rij, C. van, Tersteeg, R.J.H.A., Hauptmann, M., Kremer, L.C.M., Ronckers, C.M., Berg, M.H. van den, Bruggink, A.H., Caron, H.N., Dolsma, W.V., Grootenhuis, M.A., Hartogh, J.G. den, Hollema, N., Jongmans, M.C., Jaspers, M.W.M., Postma, A., Vijver, M.J. van de, DCOG-LATER Study Group, CCA - Cancer Treatment and Quality of Life, ARD - Amsterdam Reproduction and Development, Paediatric Oncology, Graduate School, Epidemiology and Data Science, Amsterdam Reproduction & Development (AR&D), Pediatric surgery, CCA - Cancer Treatment and quality of life, Radiation Oncology, Pediatrics, Radiotherapy, and Guided Treatment in Optimal Selected Cancer Patients (GUTS)
- Subjects
Male ,Organs at Risk ,PROTOCOL ,Cancer Research ,Neoplasms, Radiation-Induced ,meningioma ,chemistry.chemical_compound ,0302 clinical medicine ,Cancer Survivors ,Neoplasms ,Meningeal Neoplasms ,Cumulative incidence ,Child ,radiation volume ,Netherlands ,education.field_of_study ,Hazard ratio ,Age Factors ,INTENSIVE TREATMENT ,TUMORS ,Oncology ,Child, Preschool ,030220 oncology & carcinogenesis ,Female ,CNS ,radiation dose ,Rare cancers Radboud Institute for Health Sciences [Radboudumc 9] ,RADIOTHERAPY ,Adult ,Risk ,medicine.medical_specialty ,Adolescent ,childhood cancer survivors ,Population ,Clinical Neurology ,cranial radiotherapy ,Radiation Dosage ,Healthcare improvement science Radboud Institute for Health Sciences [Radboudumc 18] ,Meningioma ,Young Adult ,03 medical and health sciences ,All institutes and research themes of the Radboud University Medical Center ,SDG 3 - Good Health and Well-being ,Internal medicine ,medicine ,Humans ,education ,TERM-FOLLOW-UP ,Proportional Hazards Models ,ACUTE LYMPHOBLASTIC-LEUKEMIA ,SUBSEQUENT NEOPLASMS ,business.industry ,CENTRAL-NERVOUS-SYSTEM ,Infant, Newborn ,Infant ,Cancer ,5-YEAR SURVIVORS ,medicine.disease ,Carboplatin ,chemistry ,Relative risk ,Benign Meningioma ,Neurology (clinical) ,Cranial Irradiation ,business ,Pediatric Neuro-Oncology ,030217 neurology & neurosurgery - Abstract
BACKGROUND: Pediatric cranial radiotherapy (CrRT) markedly increases risk of meningiomas. We studied meningioma risk factors with emphasis on independent and joint effects of CrRT dose, exposed cranial volume, exposure age, and chemotherapy. METHODS: The Dutch Cancer Oncology Group-Long-Term Effects after Childhood Cancer (DCOG-LATER) cohort includes 5-year childhood cancer survivors (CCSs) whose cancers were diagnosed in 1963-2001. Histologically confirmed benign meningiomas were identified from the population-based Dutch Pathology Registry (PALGA; 1990-2015). We calculated cumulative meningioma incidence and used multivariable Cox regression and linear excess relative risk (ERR) modeling. RESULTS: Among 5843 CCSs (median follow-up: 23.3 y, range: 5.0-52.2 y), 97 developed a benign meningioma, including 80 after full- and 14 after partial-volume CrRT. Compared with CrRT doses of 1-19 Gy, no CrRT was associated with a low meningioma risk (hazard ratio [HR] = 0.04, 95% CI: 0.01-0.15), while increased risks were observed for CrRT doses of 20-39 Gy (HR = 1.66, 95% CI: 0.83-3.33) and 40+ Gy (HR = 2.81, 95% CI: 1.30-6.08). CCSs whose cancers were diagnosed before age 5 versus 10-17 years showed significantly increased risks (HR = 2.38, 95% CI: 1.39-4.07). In this dose-adjusted model, volume was not significantly associated with increased risk (HR full vs partial = 1.66, 95% CI: 0.86-3.22). Overall, the ERR/Gy was 0.30 (95% CI: 0.03-unknown). Dose effects did not vary significantly according to exposure age or CrRT volume. Cumulative incidence after any CrRT was 12.4% (95% CI: 9.8%-15.2%) 40 years after primary cancer diagnosis. Among chemotherapy agents (including methotrexate and cisplatin), only carboplatin (HR = 3.55, 95% CI: 1.62-7.78) appeared associated with meningioma risk. However, we saw no carboplatin dose-response and all 9 exposed cases had high-dose CrRT. CONCLUSION: After CrRT 1 in 8 survivors developed late meningioma by age 40 years, associated with radiation dose and exposure age, relevant for future treatment protocols and awareness among survivors and physicians.
- Published
- 2019
3. Clinical characteristics and survival patterns of subsequent sarcoma, breast cancer, and melanoma after childhood cancer in the DCOG-LATER cohort
- Author
-
DCOG-LATER Study Group
- Subjects
Male ,Adult ,Cancer Research ,Survival ,Epidemiology ,Breast Neoplasms/epidemiology ,Long-term complications ,Survival Analysis ,Childhood cancer survivors ,Subsequent malignant neoplasm ,Melanoma/epidemiology ,Cohort Studies ,Cancer Survivors ,Oncology ,Journal Article ,Humans ,Skin Neoplasms/epidemiology ,Female ,Neoplasms, Second Primary/epidemiology ,Sarcoma/epidemiology ,Child ,Netherlands - Abstract
Purpose: Childhood cancer survivors are at increased risk of developing subsequent malignant neoplasms (SMNs). We compared survival and clinical characteristics of survivors with SMNs (sarcoma, breast cancer, or melanoma) and a population-based sample of similar first malignant neoplasm (FMN) patients. Methods: We assembled three case series of solid SMNs observed in a cohort of 5-year Dutch childhood cancer survivors diagnosed 1963–2001 and followed until 2014: sarcoma (n = 45), female breast cancer (n = 41), and melanoma (n = 17). Each SMN patient was sex-, age-, and calendar year-matched to 10 FMN patients in the population-based Netherlands Cancer Registry. We compared clinical and histopathological characteristics by Fisher’s exact tests and survival by multivariable Cox regression and competing risk regression analyses. Results: Among sarcoma-SMN patients, overall survival [hazard ratio (HR) 1.88, 95% confidence interval (CI) 1.23–2.87] and sarcoma-specific mortality (HR 1.91, 95% CI 1.16–3.13) were significantly worse compared to sarcoma-FMN patients (foremost for soft-tissue sarcoma), with 15-year survival rates of 30.8% and 61.6%, respectively. Overall survival did not significantly differ for breast-SMN versus breast-FMN patients (HR 1.14, 95% CI 0.54–2.37), nor for melanoma-SMN versus melanoma-FMN patients (HR 0.71, 95% CI 0.10–5.00). No significant differences in tumor characteristics were observed between breast-SMN and breast-FMN patients. Breast-SMN patients were treated more often with mastectomy without radiotherapy/chemotherapy compared to breast-FMN patients (17.1% vs. 5.6%). Conclusions: Survival of sarcoma-SMN patients is worse than sarcoma-FMN patients. Although survival and tumor characteristics appear similar for breast-SMN and breast-FMN patients, treatment differs; breast-SMN patients less often receive breast-conserving therapy. Larger studies are necessary to substantiate these exploratory findings.
- Published
- 2019
4. The involvement of primary care physicians in care for childhood cancer survivors
- Author
-
DCOG-LATER Study Group
- Subjects
Male ,Adult ,Adolescent ,Aftercare/standards ,primary care ,Young Adult ,Surveys and Questionnaires ,Journal Article ,late effects ,Humans ,Neoplasms/therapy ,Practice Patterns, Physicians'/standards ,Pediatrics, Perinatology, and Child Health ,survivorship care ,Child ,Quality of Health Care ,Research Support, Non-U.S. Gov't ,Hematology ,Prognosis ,cancer survivorship ,Survival Rate ,Oncology ,Child, Preschool ,Case-Control Studies ,Female ,Physicians, Primary Care/statistics & numerical data ,Follow-Up Studies ,Cancer Survivors/statistics & numerical data - Abstract
Background: Childhood cancer survivors (CCS) are at risk of developing long-term morbidity, which is likely to be presented to a primary care physician (PCP). Therefore, insight into CCS's PCP-based health care use is needed. We investigated the volume and underlying health problems of PCP-based health care use and the determinants for PCP-based health care use in CCS. Procedure: Data from a Dutch cohort of 6018 eligible five-year CCS were linked to the Nivel Primary Care database, which contains detailed data from a representative sample of 10% of all Dutch PCPs. Per CCS, two matched controls were selected. Negative binomial regression was performed to compare the annual number of contacts between CCS and controls, and to identify determinants for PCP-based care use among CCS. Results: This study included 602 CCS and 1204 controls. CCS were 1.3 times more likely to contact their PCP than controls (95% CI, 1.2–1.5), up to 1.5 times at attained age over 40 years (95% CI, 1.2–1.8). CCS were 4.9 times more likely to contact their PCP for new malignancies, 3.1 for hematological conditions, and 2.8 for endocrine conditions. Female sex, higher attained age, and treatment with radiotherapy were determinants for having more PCP contacts. Conclusions: PCPs play an important role in care for CCS. CCS use more PCP-based care than matched controls, mainly for severe conditions such as malignancies, hematological, and endocrine conditions. Our results emphasize the importance of disseminating the current knowledge on long-term morbidity in CCS and on their optimal follow-up care among PCPs.
- Published
- 2019
5. Risk of benign meningioma after childhood cancer in the DCOG-LATER cohort : Contributions of radiation dose, exposed cranial volume, and age
- Author
-
Kok, Judith L, Teepen, Jop C, van Leeuwen, Flora E, Tissing, Wim J E, Neggers, Sebastian J C M M, van der Pal, Helena J, Loonen, Jacqueline J, Bresters, Dorine, Versluys, Birgitta, van den Heuvel-Eibrink, Marry M, van Dulmen-den Broeder, Eline, van der Heiden-van der Loo, Margriet, Aleman, Berthe M P, Daniels, Laurien A, Haasbeek, Cornelis J A, Hoeben, Bianca, Janssens, Geert O, Maduro, John H, Oldenburger, Foppe, van Rij, Caroline, Tersteeg, Robbert J H A, Hauptmann, Michael, Kremer, Leontien C M, Ronckers, Cécile M, and DCOG-LATER Study Group
- Subjects
Cancer Research ,Oncology ,childhood cancer survivors ,Clinical Neurology ,cranial radiotherapy ,radiation volume ,radiation dose ,meningioma - Abstract
Background. Pediatric cranial radiotherapy (CrRT) markedly increases risk of meningiomas. We studied meningioma risk factors with emphasis on independent and joint effects of CrRT dose, exposed cranial volume, exposure age, and chemotherapy. Methods. The Dutch Cancer Oncology Group-Long-Term Effects after Childhood Cancer (DCOG-LATER) cohort includes 5-year childhood cancer survivors (CCSs) whose cancers were diagnosed in 1963-2001. Histologically confirmed benign meningiomas were identified from the population-based Dutch Pathology Registry (PALGA; 1990-2015). We calculated cumulative meningioma incidence and used multivariable Cox regression and linear excess relative risk (ERR) modeling. Results. Among 5843 CCSs (median follow-up: 23.3 y, range: 5.0-52.2 y), 97 developed a benign meningioma, including 80 after full- and 14 after partial-volume CrRT. Compared with CrRT doses of 1-19 Gy, no CrRT was associated with a low meningioma risk (hazard ratio [HR] = 0.04, 95% CI: 0.01-0.15), while increased risks were observed for CrRT doses of 20-39 Gy (HR = 1.66, 95% CI: 0.83-3.33) and 40+ Gy (HR = 2.81, 95% CI: 1.30-6.08). CCSs whose cancers were diagnosed before age 5 versus 10-17 years showed significantly increased risks (HR = 2.38, 95% CI: 1.39-4.07). In this dose-adjusted model, volume was not significantly associated with increased risk (HR full vs partial = 1.66, 95% CI: 0.86-3.22). Overall, the ERR/Gy was 0.30 (95% CI: 0.03-unknown). Dose effects did not vary significantly according to exposure age or CrRT volume. Cumulative incidence after any CrRT was 12.4% (95% CI: 9.8%-15.2%) 40 years after primary cancer diagnosis. Among chemotherapy agents (including methotrexate and cisplatin), only carboplatin (HR = 3.55, 95% CI: 1.62-7.78) appeared associated with meningioma risk. However, we saw no carboplatin dose-response and all 9 exposed cases had high-dose CrRT. Conclusion. After CrRT 1 in 8 survivors developed late meningioma by age 40 years, associated with radiation dose and exposure age, relevant for future treatment protocols and awareness among survivors and physicians.
- Published
- 2019
6. Uterine function, pregnancy complications, and pregnancy outcomes among female childhood cancer survivors
- Author
-
DCOG-LATER Study Group
- Subjects
Adult ,Time Factors ,pregnancy outcomes ,Pregnancy Complications/diagnosis ,Neoplasms/pathology ,Risk Assessment ,Childhood cancer survivors ,Young Adult ,Risk Factors ,Pregnancy ,Obstetrics and Gynaecology ,Journal Article ,Humans ,Survivors ,Age of Onset ,radiotherapy ,Retrospective Studies ,uterine volume ,pregnancy complications ,Research Support, Non-U.S. Gov't ,Pregnancy Outcome ,Radiotherapy/adverse effects ,Uterus/diagnostic imaging ,Parity ,Reproductive Health ,Radiation Injuries/diagnosis ,Treatment Outcome ,Reproductive Medicine ,Female - Abstract
OBJECTIVE: To evaluate whether abdominal-pelvic radiotherapy for childhood cancer impairs uterine function and increases the risk of pregnancy complications and adverse pregnancy outcomes. DESIGN: Nested cohort study. SETTING: Not applicable. PATIENT(S): Childhood cancer survivors previously exposed to abdominal-pelvic radiotherapy (RT-exposed CCSs) as part of their treatment for childhood cancer. INTERVENTION(S): Radiotherapy-exposed CCSs (n = 55) were age- and parity-matched to nonirradiated CCSs (non-RT-exposed CCSs; n = 110) and general population controls (n = 110). MAIN OUTCOME MEASURES: Uterine volume, pregnancy complications, and pregnancy outcomes. RESULT(S): Among nulligravidous participants, median (interquartile range) uterine volume was 41.4 (18.6-52.8) mL for RT-exposed CCSs, 48.1 (35.7-61.8) mL for non-RT-exposed CCSs, and 61.3 (49.1-75.5) mL for general population controls. Radiotherapy-exposed CCSs were at increased risk of a reduced uterine volume (
- Published
- 2019
7. Clinical characteristics and survival patterns of subsequent sarcoma, breast cancer, and melanoma after childhood cancer in the DCOG-LATER cohort
- Author
-
PMC Medisch specialisten, Speerpunt, Zorg en O&O, Child Health, SCT patientenzorg, Klinische Fysica RT, Onderzoeksgroep 7, Brain, ZL Cerebrovasculaire Ziekten Medisch, DCOG-LATER Study Group, PMC Medisch specialisten, Speerpunt, Zorg en O&O, Child Health, SCT patientenzorg, Klinische Fysica RT, Onderzoeksgroep 7, Brain, ZL Cerebrovasculaire Ziekten Medisch, and DCOG-LATER Study Group
- Published
- 2019
8. The involvement of primary care physicians in care for childhood cancer survivors
- Author
-
SCT patientenzorg, Speerpunt, Zorg en O&O, Child Health, Klinische Fysica RT, PMC Medisch specialisten, DCOG-LATER Study Group, SCT patientenzorg, Speerpunt, Zorg en O&O, Child Health, Klinische Fysica RT, PMC Medisch specialisten, and DCOG-LATER Study Group
- Published
- 2019
9. Uterine function, pregnancy complications, and pregnancy outcomes among female childhood cancer survivors
- Author
-
Klinische Fysica RT, Speerpunt, Zorg en O&O, Child Health, PMC Medisch specialisten, SCT patientenzorg, DCOG-LATER Study Group, Klinische Fysica RT, Speerpunt, Zorg en O&O, Child Health, PMC Medisch specialisten, SCT patientenzorg, and DCOG-LATER Study Group
- Published
- 2019
10. Risk of benign meningioma after childhood cancer in the DCOG-LATER cohort: Contributions of radiation dose, exposed cranial volume, and age
- Author
-
PMC Medisch specialisten, SCT patientenzorg, Child Health, Zorg en O&O, MS Radiotherapie, Cancer, Klinische Fysica RT, Kok, Judith L, Teepen, Jop C, van Leeuwen, Flora E, Tissing, Wim J E, Neggers, Sebastian J C M M, van der Pal, Helena J, Loonen, Jacqueline J, Bresters, Dorine, Versluys, Birgitta, van den Heuvel-Eibrink, Marry M, van Dulmen-den Broeder, Eline, van der Heiden-van der Loo, Margriet, Aleman, Berthe M P, Daniels, Laurien A, Haasbeek, Cornelis J A, Hoeben, Bianca, Janssens, Geert O, Maduro, John H, Oldenburger, Foppe, van Rij, Caroline, Tersteeg, Robbert J H A, Hauptmann, Michael, Kremer, Leontien C M, Ronckers, Cécile M, DCOG-LATER Study Group, PMC Medisch specialisten, SCT patientenzorg, Child Health, Zorg en O&O, MS Radiotherapie, Cancer, Klinische Fysica RT, Kok, Judith L, Teepen, Jop C, van Leeuwen, Flora E, Tissing, Wim J E, Neggers, Sebastian J C M M, van der Pal, Helena J, Loonen, Jacqueline J, Bresters, Dorine, Versluys, Birgitta, van den Heuvel-Eibrink, Marry M, van Dulmen-den Broeder, Eline, van der Heiden-van der Loo, Margriet, Aleman, Berthe M P, Daniels, Laurien A, Haasbeek, Cornelis J A, Hoeben, Bianca, Janssens, Geert O, Maduro, John H, Oldenburger, Foppe, van Rij, Caroline, Tersteeg, Robbert J H A, Hauptmann, Michael, Kremer, Leontien C M, Ronckers, Cécile M, and DCOG-LATER Study Group
- Published
- 2019
11. Colorectal Adenomas and Cancers After Childhood Cancer Treatment : A DCOG-LATER Record Linkage Study
- Author
-
Teepen, J C, Kok, Judith L, van Leeuwen, Flora E, Tissing, Wim J E, Dolsma, Wil V, van der Pal, Helena J, Loonen, Jacqueline J, Bresters, Dorine, Versluys, A B, van den Heuvel-Eibrink, Marry M, van Dulmen-den Broeder, Eline, van den Berg, Marleen H, van der Heiden-van der Loo, Margriet, Hauptmann, Michael, Jongmans, M C, Overbeek, L I, van de Vijver, M J, Kremer, L C M, Ronckers, C M, Aleman, B M P, van den Berg, M H, Caron, H N, Daniels, L A, Dolsma, W, van Dulmen-den Broeder, E, Grootenhuis, M A, Haasbeek, C J, den Hartogh, J G, Hauptmann, M, van der Heiden-van der Loo, M, Hollema, N, Janssens, G O, Jaspers, M W M, Kok, J L, van Leeuwen, F E, Loonen, J, Maduro, J H, Neggers, S J C M M, Oldenburger, F, van der Pal, H J, Postma, A, Tersteeg, R J, Zsíros, J, and DCOG-LATER Study Group
- Abstract
Background: Although colorectal adenomas serve as prime target for colorectal cancer (CRC) surveillance in other high-risk groups, data on adenoma risk after childhood cancer are lacking. We evaluated the risk of histologically confirmed colorectal adenomas among childhood cancer survivors. A secondary aim was to assess CRC risk. Methods: The DCOG-LATER cohort study includes five-year Dutch childhood cancer survivors and a sibling comparison group (n = 883). Colorectal tumors were identified from the population-based Dutch Pathology Registry (PALGA). We calculated cumulative incidences of adenomas/CRCs for survivors and siblings. For adenomas, multivariable Cox regression models were used to evaluate potential risk factors. All statistical tests were two-sided. Results: Among 5843 five-year survivors (median follow-up = 24.9 years), 78 individuals developed an adenoma. Cumulative incidence by age 45 years was 3.6% (95% confidence interval [CI] = 2.2% to 5.6%) after abdominopelvic radiotherapy (AP-RT; 49 cases) vs 2.0% (95% CI = 1.3% to 2.8%) among survivors without AP-RT (28 cases; Pdifference = .07) and vs 1.0% (95% CI = 0.3% to 2.6%) among siblings (6 cases) (Pdifference = .03). Factors associated with adenoma risk were AP-RT (hazard ratio [HR] = 2.12, 95% CI = 1.24 to 3.60), total body irradiation (TBI; HR = 10.55, 95% CI = 5.20 to 21.42), cisplatin (HR = 2.13; 95% CI = 0.74 to 6.07 for
- Published
- 2018
12. Colorectal Adenomas and Cancers After Childhood Cancer Treatment: A DCOG-LATER Record Linkage Study
- Author
-
Genetica Klinische Genetica, PMC Medisch specialisten, SCT patientenzorg, Child Health, Zorg en O&O, Klinische Fysica RT, Speerpunt, MS Neonatologie, Fysica Radiotherapie Research, Onderzoeksgroep 7, Brain, ZL Cerebrovasculaire Ziekten Medisch, MS Radiotherapie, Cancer, Teepen, J C, Kok, Judith L, van Leeuwen, Flora E, Tissing, Wim J E, Dolsma, Wil V, van der Pal, Helena J, Loonen, Jacqueline J, Bresters, Dorine, Versluys, A B, van den Heuvel-Eibrink, Marry M, van Dulmen-den Broeder, Eline, van den Berg, Marleen H, van der Heiden-van der Loo, Margriet, Hauptmann, Michael, Jongmans, M C, Overbeek, L I, van de Vijver, M J, Kremer, L C M, Ronckers, C M, Aleman, B M P, van den Berg, M H, Caron, H N, Daniels, L A, Dolsma, W, van Dulmen-den Broeder, E, Grootenhuis, M A, Haasbeek, C J, den Hartogh, J G, Hauptmann, M, van der Heiden-van der Loo, M, Hollema, N, Janssens, G O, Jaspers, M W M, Kok, J L, van Leeuwen, F E, Loonen, J, Maduro, J H, Neggers, S J C M M, Oldenburger, F, van der Pal, H J, Postma, A, Tersteeg, R J, Zsíros, J, DCOG-LATER Study Group, Genetica Klinische Genetica, PMC Medisch specialisten, SCT patientenzorg, Child Health, Zorg en O&O, Klinische Fysica RT, Speerpunt, MS Neonatologie, Fysica Radiotherapie Research, Onderzoeksgroep 7, Brain, ZL Cerebrovasculaire Ziekten Medisch, MS Radiotherapie, Cancer, Teepen, J C, Kok, Judith L, van Leeuwen, Flora E, Tissing, Wim J E, Dolsma, Wil V, van der Pal, Helena J, Loonen, Jacqueline J, Bresters, Dorine, Versluys, A B, van den Heuvel-Eibrink, Marry M, van Dulmen-den Broeder, Eline, van den Berg, Marleen H, van der Heiden-van der Loo, Margriet, Hauptmann, Michael, Jongmans, M C, Overbeek, L I, van de Vijver, M J, Kremer, L C M, Ronckers, C M, Aleman, B M P, van den Berg, M H, Caron, H N, Daniels, L A, Dolsma, W, van Dulmen-den Broeder, E, Grootenhuis, M A, Haasbeek, C J, den Hartogh, J G, Hauptmann, M, van der Heiden-van der Loo, M, Hollema, N, Janssens, G O, Jaspers, M W M, Kok, J L, van Leeuwen, F E, Loonen, J, Maduro, J H, Neggers, S J C M M, Oldenburger, F, van der Pal, H J, Postma, A, Tersteeg, R J, Zsíros, J, and DCOG-LATER Study Group
- Published
- 2018
13. Risk and Temporal Changes of Heart Failure Among 5-Year Childhood Cancer Survivors: a DCOG-LATER Study.
- Author
-
(Lieke) Feijen, E. A. M., Font-Gonzalez, Anna, Van der Pal, Helena J. H., Kok, Wouter E. M., Geskus, Ronald B., Ronckers, Cécile M., Bresters, Dorine, van Dalen, Elvira C., van Dulmen-den Broeder, Eline, van den Berg, Marleen H., van der Heiden-van der Loo, Margriet, van den Heuvel-Eibrink, Marry M., van Leeuwen, Flora E., Loonen, Jacqueline J., Neggers, Sebastian J. C. M. M., Versluys, A. B. (Birgitta), Tissing, Wim J. E., Kremer, Leontien C. M., Feijen, E A M Lieke, and DCOG‐LATER Study Group
- Published
- 2019
- Full Text
- View/download PDF
14. Long-Term Risk of Subsequent Malignant Neoplasms After Treatment of Childhood Cancer in the DCOG LATER Study Cohort: Role of Chemotherapy.
- Author
-
Teepen, Jop C., van Leeuwen, Flora E., Tissing, Wim J., van Dulmen-den Broeder, Eline, van den Heuvel-Eibrink, Marry M., van der Pal, Helena J., Loonen, Jacqueline J., Bresters, Dorine, Versluys, Birgitta, Neggers, Sebastian J. C. M. M., Jaspers, Monique W. M., Hauptmann, Michael, van der Heiden-van der Loo, Margriet, Visser, Otto, Kremer, Leontien C. M., Ronckers, Cécile M., and DCOG LATER Study Group
- Published
- 2017
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.